Based on the ProPhase Labs Inc stock forecast from 0 analysts, the average analyst target price for ProPhase Labs Inc is not available over the next 12 months. ProPhase Labs Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ProPhase Labs Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, ProPhase Labs Inc’s stock price was USD 0.31. ProPhase Labs Inc’s stock price has changed by +28.54% over the past week, -31.88% over the past month and -95.27% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for ProPhase Labs Inc
No recent average analyst rating found for ProPhase Labs Inc
Company Overview ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular and DNA testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Read Less
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual ...Read More
Frequently Asked Questions About ProPhase Labs Inc (PRPH) Stock
Stock Target Advisor's fundamental analysis for ProPhase Labs Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on PRPH's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PRPH's stock to indicate what its average analyst target is.
PRPH stock's Price/Earning ratio is 13.63.
Our analysis grades PRPH stock's Price / Earning ratio at D-. This means that PRPH stock's Price/Earning ratio is above 39% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this PRPH may be fairly valued for its sector
The last closing price of PRPH's stock was USD 0.31.
The most recent market capitalization for PRPH is USD 0.01B.
Unfortunately we do not have enough analyst data on PRPH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProPhase Labs Inc's stock.
As per our most recent records ProPhase Labs Inc has 113 Employees.
ProPhase Labs Inc's registered address is 711 Stewart Avenue, Garden City, NY, United States, 11530.
You can get more information about it from ProPhase Labs Inc's website at https://www.prophaselabs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ProPhase Labs Inc (PRPH) Stock
Stock Target Advisor's fundamental analysis for ProPhase Labs Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on PRPH's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PRPH's stock to indicate what its average analyst target is.
PRPH stock's Price/Earning ratio is 13.63.
Our analysis grades PRPH stock's Price / Earning ratio at D-. This means that PRPH stock's Price/Earning ratio is above 39% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this PRPH may be fairly valued for its sector
The last closing price of PRPH's stock was USD 0.31.
The most recent market capitalization for PRPH is USD 0.01B.
Unfortunately we do not have enough analyst data on PRPH's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ProPhase Labs Inc's stock.
As per our most recent records ProPhase Labs Inc has 113 Employees.
ProPhase Labs Inc's registered address is 711 Stewart Avenue, Garden City, NY, United States, 11530.
You can get more information about it from ProPhase Labs Inc's website at https://www.prophaselabs.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
